Literature DB >> 12673209

RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis.

Jung-Eun Kim1, Song-Ja Kim, Ha-Won Jeong, Byung-Heon Lee, Je-Yong Choi, Rang-Woon Park, Jae Yong Park, In-San Kim.   

Abstract

Beta ig-h3 is a transforming growth factor-beta (TGF-beta)-induced cell-adhesive molecule and has an RGD sequence at its C-terminus. A previous report suggested that beta ig-h3 normally undergoes carboxy-terminal processing that results in the loss of the RGD sequence. RGD peptides appear to play various roles in cell function. Here we show that the RGD peptides released from beta ig-h3 may facilitate TGF-beta-induced apoptosis. We found that carboxy-terminal cleavage of beta ig-h3 occurred after its secretion, and that overexpression of the wild-type beta ig-h3 induced apoptosis, unlike the C-terminal deleted but RGD-containing mutant beta ig-h3, which is resistant to C-terminal processing. The beta ig-h3-induced apoptosis was abolished by either deletion of the RGD sequence or mutation of RGD to RAE. Synthetic peptides of ERGDEL and GRGDSP derived from beta ig-h3 and fibronectin, respectively, also induced apoptosis, unlike ERGEEL and GRGESP. Culture supernatants of cells overexpressing beta ig-h3 filtered to isolate molecules smaller than 3 kDa also induced apoptosis. A fusion protein composed of the N-terminal 100 amino acids of fibronectin and the RGD-containing C-terminal part of beta ig-h3 was also subjected to C-terminal cleavage and overexpression resulted in apoptosis. The anti-beta ig-h3 antibody blocks TGF-beta-induced apoptosis. Thus, beta ig-h3 may be important in regulating cell apoptosis by providing soluble RGD peptides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673209     DOI: 10.1038/sj.onc.1206269

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Crystallization and preliminary crystallographic analysis of the fourth FAS1 domain of human BigH3.

Authors:  Ji-Ho Yoo; EungKweon Kim; Jongsun Kim; Hyun-Soo Cho
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-09-29

2.  Construction of eukaryotic plasmid expressing human TGFBI and its influence on human corneal epithelial cells.

Authors:  Jing-Yi Niu; Jing Liu; Lian Liu; Yi-Yang Lü; Jian-Su Chen; Jin-Tang Xu; Jing-Xiang Zhong
Journal:  Int J Ophthalmol       Date:  2012-02-18       Impact factor: 1.779

3.  Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature.

Authors:  Maria E Akerman; Jan Pilch; David Peters; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-01       Impact factor: 11.205

4.  Detection of differentially expressed basal cell proteins by mass spectrometry.

Authors:  Viktor Todorović; Bhushan V Desai; Richard A Eigenheer; Taofei Yin; Evangeline V Amargo; Milan Mrksich; Kathleen J Green; Melanie J Schroeder Patterson
Journal:  Mol Cell Proteomics       Date:  2009-11-30       Impact factor: 5.911

5.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

6.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

7.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

8.  TGFBI (βIG-H3) is a diabetes-risk gene based on mouse and human genetic studies.

Authors:  Bing Han; Hongyu Luo; John Raelson; Jie Huang; Yun Li; Johanne Tremblay; Bing Hu; Shijie Qi; Jiangping Wu
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

Review 9.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

10.  Denaturation and solvent effect on the conformation and fibril formation of TGFBIp.

Authors:  Heather L Grothe; Morgan R Little; Angela S Cho; Andrew J W Huang; Ching Yuan
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.